Enliven Therapeutics Past Earnings Performance
Past criteria checks 0/6
Enliven Therapeutics's earnings have been declining at an average annual rate of -37.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-37.4%
Earnings growth rate
24.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -29.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Enliven Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -85 | 21 | 78 |
| 30 Jun 24 | 0 | -83 | 20 | 76 |
| 31 Mar 24 | 0 | -80 | 18 | 73 |
| 31 Dec 23 | 0 | -72 | 18 | 65 |
| 30 Sep 23 | 0 | -62 | 16 | 55 |
| 30 Jun 23 | 0 | -52 | 15 | 43 |
| 31 Mar 23 | 0 | -44 | 11 | 36 |
| 31 Dec 22 | 0 | -38 | 8 | 31 |
| 30 Sep 22 | 0 | -37 | 7 | 30 |
| 31 Dec 21 | 0 | -25 | 4 | 20 |
Quality Earnings: ELVN is currently unprofitable.
Growing Profit Margin: ELVN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELVN is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare ELVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELVN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ELVN has a negative Return on Equity (-29.55%), as it is currently unprofitable.